Biomarkers for Osteoarthritis: Current Position and Steps Towards Further Validation

Overview

Journal Best Pract Res Clin Rheumatol

Publisher Elsevier

Specialty Rheumatology

Date 2014 May 6

PMID 24792945

Citations 96

Authors

David J Hunter

Michael Nevitt

Elena Losina

Virginia Kraus

Affiliations

Soon will be listed here.

Abstract

Historically disease knowledge development and treatment innovation in osteoarthritis (OA) has been considered to be slow. One of the many reasons purported as responsible for this slow pace has been the alleged lack of valid and responsive biomarkers to ascertain efficacy, which itself has been dependent upon the slow evolution of the understanding of the complex nature of joint tissue biology. This narrative review outlines the rationale for why we need OA biomarkers with regard to biomarker validation and qualification. The main biomarkers in current development for OA are biochemical and imaging markers. We describe an approach to biomarker validation and qualification for OA clinical trials that has recently commenced with the Foundation of NIH OA Biomarkers Consortium study cosponsored by the Osteoarthritis Research Society International (OARSI). With this approach we endeavor to identify, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics for osteoarthritis.

Citing Articles

Foundations of a knee joint digital twin from qMRI biomarkers for osteoarthritis and knee replacement.

Hoyer G, Gao K, Gassert F, Luitjens J, Jiang F, Majumdar S NPJ Digit Med. 2025; 8(1):118.

PMID: 39984725 PMC: 11845592. DOI: 10.1038/s41746-025-01507-3.

Obese Patients Do Not Benefit from Bone Marrow Aspiration Concentrate Injection for Knee Osteoarthritis: A Prospective Cohort Study of 68 Patients.

Muthu S, Thangavel P, Duraisamy S, Jha S, Ramanathan K, Yadav S Indian J Orthop. 2024; 59(1):92-100.

PMID: 39735869 PMC: 11680530. DOI: 10.1007/s43465-024-01305-1.

The design of a sample rapid magnetic resonance imaging (MRI) acquisition protocol supporting assessment of multiple articular tissues and pathologies in knee osteoarthritis.

Eckstein F, Walter-Rittel T, Chaudhari A, Brisson N, Maleitzke T, Duda G Osteoarthr Cartil Open. 2024; 6(3):100505.

PMID: 39183946 PMC: 11342198. DOI: 10.1016/j.ocarto.2024.100505.

Sexual dimorphism in peri-articular tissue anatomy - More keys to understanding sex-differences in osteoarthritis?.

Eckstein F, Putz R, Wirth W Osteoarthr Cartil Open. 2024; 6(3):100485.

PMID: 38946793 PMC: 11214405. DOI: 10.1016/j.ocarto.2024.100485.

Pathological progression of osteoarthritis: a perspective on subchondral bone.

Li X, Chen W, Liu D, Chen P, Wang S, Li F Front Med. 2024; 18(2):237-257.

PMID: 38619691 DOI: 10.1007/s11684-024-1061-y.

References

Lesko L, Atkinson Jr A . Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001; 41:347-66. DOI: 10.1146/annurev.pharmtox.41.1.347. View

Zhang W, Nuki G, Moskowitz R, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18(4):476-99. DOI: 10.1016/j.joca.2010.01.013. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Hunter D, Zhang Y, Tu X, Lavalley M, Niu J, Amin S . Change in joint space width: hyaline articular cartilage loss or alteration in meniscus?. Arthritis Rheum. 2006; 54(8):2488-95. DOI: 10.1002/art.22016. View

Altar C . The Biomarkers Consortium: on the critical path of drug discovery. Clin Pharmacol Ther. 2008; 83(2):361-4. DOI: 10.1038/sj.clpt.6100471. View

Conaghan P, Hunter D, Maillefert J, Reichmann W, Losina E . Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage. 2011; 19(5):606-10. PMC: 3260466. DOI: 10.1016/j.joca.2011.02.018. View

Richter W . Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imaging. 2006; 33 Suppl 1:6-10. DOI: 10.1007/s00259-006-0129-z. View

. Prevalence of disabilities and associated health conditions among adults--United States, 1999. MMWR Morb Mortal Wkly Rep. 2001; 50(7):120-5. View

Guermazi A, Burstein D, Conaghan P, Eckstein F, Le Graverand-Gastineau M, Keen H . Imaging in osteoarthritis. Rheum Dis Clin North Am. 2008; 34(3):645-87. DOI: 10.1016/j.rdc.2008.04.006. View

10.

Bauer D, Hunter D, Abramson S, Attur M, Corr M, Felson D . Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006; 14(8):723-7. DOI: 10.1016/j.joca.2006.04.001. View

11.

DiMasi J, Hansen R, Grabowski H . The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22(2):151-85. DOI: 10.1016/S0167-6296(02)00126-1. View

12.

Peterfy C, Schneider E, Nevitt M . The osteoarthritis initiative: report on the design rationale for the magnetic resonance imaging protocol for the knee. Osteoarthritis Cartilage. 2008; 16(12):1433-41. PMC: 3048821. DOI: 10.1016/j.joca.2008.06.016. View

13.

Lester G . Clinical research in OA--the NIH Osteoarthritis Initiative. J Musculoskelet Neuronal Interact. 2009; 8(4):313-4. View

14.

Bingham 3rd C, Buckland-Wright J, Garnero P, Cohen S, Dougados M, Adami S . Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee.... Arthritis Rheum. 2006; 54(11):3494-507. DOI: 10.1002/art.22160. View

15.

Bruyere O, Pavelka K, Rovati L, Gatterova J, Giacovelli G, Olejarova M . Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2007; 16(2):254-60. DOI: 10.1016/j.joca.2007.06.011. View

16.

Hunter D, Zhang W, Conaghan P, Hirko K, Menashe L, Li L . Systematic review of the concurrent and predictive validity of MRI biomarkers in OA. Osteoarthritis Cartilage. 2011; 19(5):557-88. PMC: 3268360. DOI: 10.1016/j.joca.2010.10.029. View

17.

Alpert J . The Vioxx debacle. Am J Med. 2005; 118(3):203-4. DOI: 10.1016/j.amjmed.2005.01.020. View

18.

Revkin J, Shear C, Pouleur H, Ryder S, Orloff D . Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Rev. 2007; 59(1):40-53. DOI: 10.1124/pr.59.1.1. View

19.

Hunter D, Zhang W, Conaghan P, Hirko K, Menashe L, Reichmann W . Responsiveness and reliability of MRI in knee osteoarthritis: a meta-analysis of published evidence. Osteoarthritis Cartilage. 2011; 19(5):589-605. PMC: 3625963. DOI: 10.1016/j.joca.2010.10.030. View

20.

Lassere M . A users guide to measurement in medicine. Osteoarthritis Cartilage. 2006; 14 Suppl A:A10-3. DOI: 10.1016/j.joca.2006.02.021. View